S 18326: a thrombin inhibitor that shows potential for oral treatment of thromboembolic disorders.
Antivitamin K agents are currently the only orally available anticoagulant compounds. During the past two decades, important research has focused on the discovery of a direct, orally active thrombin inhibitor. In 1991, DuP 714, a boro arginine derivative, was shown to possess anticoagulant activity in different animal species after oral administration. S 18326, structurally related to DuP 714, is a further potent thrombin inhibitor. Moreover, its improved selectivity profile, associated with potent anticoagulant and antithrombotic properties, favours potential development of this compound for venous, as well as arterial, thromboembolism.
De Nanteuil
G
G
Division D of Medicinal Chemistry, Institut de Recherche Servier, 11 rue des Moulineaux, 92150 Suresnes, France.
Verbeuren
T J
TJ